...
首页> 外文期刊>Gynecologic Oncology: An International Journal >Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions
【24h】

Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions

机译:实时定量PCR评估潜在可疑乳腺癌恶性病变妇女队列中细针抽吸术前标本中激素受体和HER2的状态

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives Reliable assessment of estrogen, progesterone (ER and PR), and HER2 receptor status are essential in breast cancer (BC) treatment. Immunohistochemical methods are limited by intra- and inter-laboratory variability. Furthermore, current methods are not the ideal approach for reproducing the biological continuum of ER, PR, and HER2 receptor levels, due to their intrinsic, semi-quantitative nature, relying in part on subjective interpretation. Methods In the present study, we tested a molecular approach to define ER, PR, and HER2 status in fine-needle-aspirate (FNA) samples from patients with early BC. We performed flow cytometry analysis on 88 FNA specimens from suspect BC patients to determine cellularity. We used quantitative Real Time PCR (QRT-PCR) to assess ER, PR, HER2 status, and qPCR for HER2 gene copy number (GCN). Results ER and PR mRNA levels showed a highly significant correlation with IHC data on surgical samples. qPCR showed greater accuracy than IHC in defining HER2 status. QRT-PCR defined better than IHC the continuous spectrum of the expression of the assessed receptors. Moreover, PCR analysis demonstrated a strict correlation between HER2 status and higher levels of its transcript, correctly stratifying HER2 + and HER2 - patients. Finally, there was a strongly significant agreement between HER2 GCN assessed on FNA specimens by qPCR and FISH data obtained on pathological tissue specimens. Conclusions The present results support a comprehensive approach to determine ER, PR, and HER2 status by PCR (QRT-PCR and qPCR) in FNA specimens, with high relevance for therapeutic strategies like neoadjuvant treatment.
机译:目的可靠评估雌激素,孕酮(ER和PR)和HER2受体的状态对于乳腺癌(BC)治疗至关重要。免疫组织化学方法受到实验室内和实验室间变异性的限制。此外,由于部分内在的,半定量的性质,目前的方法不是再现ER,PR和HER2受体水平的生物学连续性的理想方法。方法在本研究中,我们测试了一种分子方法来定义早期BC患者的细针抽吸(FNA)样品中的ER,PR和HER2状态。我们对88名疑似BC患者的FNA标本进行了流式细胞仪分析,以确定其细胞性。我们使用定量实时PCR(QRT-PCR)来评估ER,PR,HER2状态和qPCR的HER2基因拷贝数(GCN)。结果ER和PR mRNA水平与手术样本的IHC数据高度相关。在确定HER2状态方面,qPCR显示出比IHC更高的准确性。 QRT-PCR比IHC更好地定义了评估受体表达的连续光谱。此外,PCR分析表明HER2状态与其转录物的较高水平之间存在严格的相关性,从而正确区分了HER2 +和HER2-患者。最后,通过qPCR在FNA标本上评估的HER2 GCN与在病理组织标本上获得的FISH数据之间存在强烈的显着一致性。结论本研究结果支持通过FNA标本中的PCR(QRT-PCR和qPCR)确定ER,PR和HER2状态的综合方法,与新辅助治疗等治疗策略高度相关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号